Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer

Seminars in Oncology

Volumn 24, Issue 1 SUPPL. 3, 1997, Pages

  Hortobagyi, G N ^a   Holmes, F A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0031058858     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)